EDUCATION CENTER

Purpose of the visit

A peptide consultation is a medical visit, not a shopping appointment. The goal is to decide whether any peptide is appropriate—and if not, what should happen instead.

Bring a clear goal: recovery from a specific injury, body composition, sleep-related recovery, sexual wellness, or curiosity after reading education pages. Vague “I want peptides” is harder to turn into a safe plan.

How to prepare

List current medications and supplements, surgeries, cancer history, and whether you are pregnant, trying to conceive, or breastfeeding.

Upload or bring recent labs if you have them. Note injuries, PT already tried, and training schedule. The peptide consultation checklist in Downloads is built for this.

What happens during the consult

Your clinician reviews history, medications, and goals, then screens for contraindications. You should leave knowing whether a peptide is on the table, deferred for labs, or not recommended.

Expect questions about sleep, nutrition, alcohol, and other Vita Bella therapies you already use. Combinations are designed on purpose.

Labs and next steps

If labs are needed, therapy waits for results that change the decision. GH-axis peptides in particular often need baseline context before dosing.

Follow-up timing is part of the plan. Ask who to message for injection questions and what symptoms should trigger a same-day call.

If a peptide is prescribed

Review injection or reconstitution resources before the first dose. Use only the pharmacy product dispensed for you.

Do not add extra peptides, SARMs, or research chemicals to “boost” the protocol. Report side effects early so the plan can be adjusted.

If a peptide is not the right tool

That is a common and appropriate outcome. Next steps may include PT, TRT or hormone evaluation, GLP-1 care, sleep workup, or education only.

You can still use the Peptide Therapy and Education Center pages to stay informed if a peptide becomes relevant later.

FAQs

References

1. 1. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707.

2. 2. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

3. 3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.

4. 4. Molitch ME, et al. Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.

5. 5. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.

6. 6. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.

Related guides